問題一覧
1
A major neuroendocrine system at controls reactions to stress and regulates many body processes, including digestion, immune responses, mood and emotions, sexual activity, and energy storage and expenditure. It is the common mechanism for interactions among glands, hormones, and parts of the midbrain that mediate the general adaptation syndrome (GAS)
2
The paraventricular nucleus of the hypothalamus, anterior lobe of the pituitary gland, and the adrenal cortex
3
Paraventricular nucleus of the hypothalamus
4
Anterior lobe of the pituitary gland
5
Adrenal cortex
6
Negative feedback
7
CRH and vasopressin; proopiomelanocortin (POMC) into ACTH and β-endorphins.
8
adrenal medulla; upregulation
9
positively; pituitary; increase
10
Leuprolide, Goserelin, Nafarelin, and Histrelin
11
Leuprolide, Goserelin, Nafarelin, and Histrelin
12
Leuprolide, Goserelin, Nafarelin, and Histrelin
13
ACTH
14
↑ release of ACTH; ↓ ACTH release
15
Hypothalamus releases CRH to stimulate ACTH in the anterior pituitary to convert cholesterol to pregnenolone in the adrenal cortex, which results in the synthesis of adrenal steroids and adrenal androgens
16
Mainly to help differentiate Addison’s disease from 2⁰ adrenal failure [caused by a pituitary issue]
17
None with short term use; with longer use s/e similar to using steroids chronically
18
GH; Somatostatin
19
Growth hormone releasing hormone [GHRH]
20
GH effects exerted directly on its target organs, yet some effects mediated through insulin like growth factors 1 & 2
21
Growth hormone releasing hormone [GHRH]
22
SQ or IM; IGF-1
23
Edema, arthralgias, ↑ risk of DM
24
Children with closed epiphyses, those with diabetic eye disease, patients with Prader-Willi that are obese
25
GH & TSH; insulin, glucagon & gastrin
26
Octreotide & Lanreotide
27
Diarrhea, abdominal pain, gas, nausea & steatorrhea
28
FSH & LH
29
GnRH
30
FSH/LH
31
hMG
32
hCG
33
Urofollitropin
34
Follitropin [α & β]
35
Choriogonadotropin α
36
Ovarian enlargement & possible hyperstimulation
37
Prolactin
38
Metoclopramide; antagonists
39
galactorrhea & hypogonadism
40
Bromocriptine or Cabergoline
41
hypothalamus;posterior pituitary
42
IV
43
Oxytocin
44
Antidiuretic hormone [ADH]
45
H2O intoxication & low Na+
46
Desmopressin [DDAVP]
47
Principal function/actions of the thyroid gland
48
TSH (thyroid-stimulating hormone)
49
T3 and T4
50
TSH (thyroid-stimulating hormone)
51
High TSH level
52
Low TSH level
53
T3 (or free T3) (triiodothyronine)
54
T4 (or free T4) (thyroxine)
55
Clinical presentation and therapy for hypothyroidism
56
Hyperthyroidism
57
Thyrotoxicosis
58
Methimazole and propylthiouracil
59
Beta blockers (propranolol)
60
A high level of T-4 and a low level of TSH
61
Graves disease
62
Grave's disease
63
Beta-blockers (propranolol and metoprolol), Antithyroid medications (methimazole and propylthiouracil), Radioiodine therapy, and thyroidectomy
64
Thyroid storm
65
Common symptoms of Thyroid Storm
66
Medications and treatment therapies for Thyroid Storm
67
Pharmacokinetics of Methimazole
68
Side Effects/Adverse Effects of Methimazole
69
May interact with blood thinners and digoxin
70
CI for Methimazole
71
Dosing Considerations for Methimazole
72
Pharmacokinetics of Propylthiouracil
73
Side Effects/Adverse Effects of Propylthiouracil
74
May interact with blood thinners and digoxin
75
Dosing Considerations for Propylthiouracil
76
overweight
77
obese
78
severe obesity
79
85th percentile
80
95th percentile
81
-BMI >25 and 1 or more CV weight related risk factor or condition -BMI >/= to 30, regardless of the presence of cardiometabolic risk factors -Waist circumference is a significant parameter that should be assessed in all overweight/obese patients -In the US, the cutoff is 40 inches for men and 35 inches for women [for Asian Americans the cut off is 5” less]
82
Anorexiants
83
MOA of Anorexiants
84
Pharmacokinetics of Anorexiants
85
AE of Anorexiants
86
Anorexiants
87
MOA of Orlistat [Xenical/Alli]
88
Diethylpropion [Tenuate] Phentermine [Adipex-P]
89
Orlistat [Xenical/Alli]
90
Pharmacokinetics of Lipase Inhibitors
91
AE of Lipase Inhibitors
92
CI for Lipase Inhibitors
93
Lorcaserin [Belviq]
94
Serotonin Agonists
95
MOA of Serotonin Agonists
96
Pharmacokinetics of Serotonin Agonists
97
AE of Serotonin Agonists
98
Considerations for Serotonin Agonists
99
Naltrexone ER/Bupropion ER [Contrave]
100
Naltrexone ER/Bupropion ER [Contrave]
August 2019 Special PE Exam
August 2019 Special PE Exam
ユーザ名非公開 · 93問 · 13日前August 2019 Special PE Exam
August 2019 Special PE Exam
93問 • 13日前TDM
TDM
ayrika · 94問 · 1ヶ月前TDM
TDM
94問 • 1ヶ月前TOXINS
TOXINS
ayrika · 57問 · 1ヶ月前TOXINS
TOXINS
57問 • 1ヶ月前薬学
薬学
ユーザ名非公開 · 15問 · 1ヶ月前薬学
薬学
15問 • 1ヶ月前CRM Y FISIOLOGÍA DE VUELO SKYVIP
CRM Y FISIOLOGÍA DE VUELO SKYVIP
ユーザ名非公開 · 50問 · 2ヶ月前CRM Y FISIOLOGÍA DE VUELO SKYVIP
CRM Y FISIOLOGÍA DE VUELO SKYVIP
50問 • 2ヶ月前TOXINS
TOXINS
ユーザ名非公開 · 57問 · 2ヶ月前TOXINS
TOXINS
57問 • 2ヶ月前DRUG OF ABUSE
DRUG OF ABUSE
ユーザ名非公開 · 95問 · 2ヶ月前DRUG OF ABUSE
DRUG OF ABUSE
95問 • 2ヶ月前TOXICOLOGY
TOXICOLOGY
ユーザ名非公開 · 77問 · 2ヶ月前TOXICOLOGY
TOXICOLOGY
77問 • 2ヶ月前Spelling test 4 - hypo hyper logy
Spelling test 4 - hypo hyper logy
ユーザ名非公開 · 10問 · 2ヶ月前Spelling test 4 - hypo hyper logy
Spelling test 4 - hypo hyper logy
10問 • 2ヶ月前OTHER GLANDS
OTHER GLANDS
ユーザ名非公開 · 8問 · 2ヶ月前OTHER GLANDS
OTHER GLANDS
8問 • 2ヶ月前SEX GLANDS
SEX GLANDS
ユーザ名非公開 · 35問 · 2ヶ月前SEX GLANDS
SEX GLANDS
35問 • 2ヶ月前PARATHYROID GLAND
PARATHYROID GLAND
ユーザ名非公開 · 12問 · 2ヶ月前PARATHYROID GLAND
PARATHYROID GLAND
12問 • 2ヶ月前THYROID GLAND
THYROID GLAND
ユーザ名非公開 · 71問 · 2ヶ月前THYROID GLAND
THYROID GLAND
71問 • 2ヶ月前PITUITARY GLAND PART 2
PITUITARY GLAND PART 2
ユーザ名非公開 · 5問 · 2ヶ月前PITUITARY GLAND PART 2
PITUITARY GLAND PART 2
5問 • 2ヶ月前M11c15
M11c15
مقطع من الاغاني عراقيه قصيره · 13問 · 2ヶ月前M11c15
M11c15
13問 • 2ヶ月前GEN BIO
GEN BIO
Jamila Escudero · 23問 · 3ヶ月前GEN BIO
GEN BIO
23問 • 3ヶ月前Strong Iodine Solution
Strong Iodine Solution
HERSHEY VALERIE BERNARDINO · 60問 · 4ヶ月前Strong Iodine Solution
Strong Iodine Solution
60問 • 4ヶ月前nstp
nstp
ユーザ名非公開 · 25問 · 4ヶ月前nstp
nstp
25問 • 4ヶ月前LEUKOPOIESIS II AND MONOPOIESIS MCQ
LEUKOPOIESIS II AND MONOPOIESIS MCQ
Jef Marc Valencia · 39問 · 4ヶ月前LEUKOPOIESIS II AND MONOPOIESIS MCQ
LEUKOPOIESIS II AND MONOPOIESIS MCQ
39問 • 4ヶ月前Clearance
Clearance
Almira Coleen · 24問 · 4ヶ月前Clearance
Clearance
24問 • 4ヶ月前問題一覧
1
A major neuroendocrine system at controls reactions to stress and regulates many body processes, including digestion, immune responses, mood and emotions, sexual activity, and energy storage and expenditure. It is the common mechanism for interactions among glands, hormones, and parts of the midbrain that mediate the general adaptation syndrome (GAS)
2
The paraventricular nucleus of the hypothalamus, anterior lobe of the pituitary gland, and the adrenal cortex
3
Paraventricular nucleus of the hypothalamus
4
Anterior lobe of the pituitary gland
5
Adrenal cortex
6
Negative feedback
7
CRH and vasopressin; proopiomelanocortin (POMC) into ACTH and β-endorphins.
8
adrenal medulla; upregulation
9
positively; pituitary; increase
10
Leuprolide, Goserelin, Nafarelin, and Histrelin
11
Leuprolide, Goserelin, Nafarelin, and Histrelin
12
Leuprolide, Goserelin, Nafarelin, and Histrelin
13
ACTH
14
↑ release of ACTH; ↓ ACTH release
15
Hypothalamus releases CRH to stimulate ACTH in the anterior pituitary to convert cholesterol to pregnenolone in the adrenal cortex, which results in the synthesis of adrenal steroids and adrenal androgens
16
Mainly to help differentiate Addison’s disease from 2⁰ adrenal failure [caused by a pituitary issue]
17
None with short term use; with longer use s/e similar to using steroids chronically
18
GH; Somatostatin
19
Growth hormone releasing hormone [GHRH]
20
GH effects exerted directly on its target organs, yet some effects mediated through insulin like growth factors 1 & 2
21
Growth hormone releasing hormone [GHRH]
22
SQ or IM; IGF-1
23
Edema, arthralgias, ↑ risk of DM
24
Children with closed epiphyses, those with diabetic eye disease, patients with Prader-Willi that are obese
25
GH & TSH; insulin, glucagon & gastrin
26
Octreotide & Lanreotide
27
Diarrhea, abdominal pain, gas, nausea & steatorrhea
28
FSH & LH
29
GnRH
30
FSH/LH
31
hMG
32
hCG
33
Urofollitropin
34
Follitropin [α & β]
35
Choriogonadotropin α
36
Ovarian enlargement & possible hyperstimulation
37
Prolactin
38
Metoclopramide; antagonists
39
galactorrhea & hypogonadism
40
Bromocriptine or Cabergoline
41
hypothalamus;posterior pituitary
42
IV
43
Oxytocin
44
Antidiuretic hormone [ADH]
45
H2O intoxication & low Na+
46
Desmopressin [DDAVP]
47
Principal function/actions of the thyroid gland
48
TSH (thyroid-stimulating hormone)
49
T3 and T4
50
TSH (thyroid-stimulating hormone)
51
High TSH level
52
Low TSH level
53
T3 (or free T3) (triiodothyronine)
54
T4 (or free T4) (thyroxine)
55
Clinical presentation and therapy for hypothyroidism
56
Hyperthyroidism
57
Thyrotoxicosis
58
Methimazole and propylthiouracil
59
Beta blockers (propranolol)
60
A high level of T-4 and a low level of TSH
61
Graves disease
62
Grave's disease
63
Beta-blockers (propranolol and metoprolol), Antithyroid medications (methimazole and propylthiouracil), Radioiodine therapy, and thyroidectomy
64
Thyroid storm
65
Common symptoms of Thyroid Storm
66
Medications and treatment therapies for Thyroid Storm
67
Pharmacokinetics of Methimazole
68
Side Effects/Adverse Effects of Methimazole
69
May interact with blood thinners and digoxin
70
CI for Methimazole
71
Dosing Considerations for Methimazole
72
Pharmacokinetics of Propylthiouracil
73
Side Effects/Adverse Effects of Propylthiouracil
74
May interact with blood thinners and digoxin
75
Dosing Considerations for Propylthiouracil
76
overweight
77
obese
78
severe obesity
79
85th percentile
80
95th percentile
81
-BMI >25 and 1 or more CV weight related risk factor or condition -BMI >/= to 30, regardless of the presence of cardiometabolic risk factors -Waist circumference is a significant parameter that should be assessed in all overweight/obese patients -In the US, the cutoff is 40 inches for men and 35 inches for women [for Asian Americans the cut off is 5” less]
82
Anorexiants
83
MOA of Anorexiants
84
Pharmacokinetics of Anorexiants
85
AE of Anorexiants
86
Anorexiants
87
MOA of Orlistat [Xenical/Alli]
88
Diethylpropion [Tenuate] Phentermine [Adipex-P]
89
Orlistat [Xenical/Alli]
90
Pharmacokinetics of Lipase Inhibitors
91
AE of Lipase Inhibitors
92
CI for Lipase Inhibitors
93
Lorcaserin [Belviq]
94
Serotonin Agonists
95
MOA of Serotonin Agonists
96
Pharmacokinetics of Serotonin Agonists
97
AE of Serotonin Agonists
98
Considerations for Serotonin Agonists
99
Naltrexone ER/Bupropion ER [Contrave]
100
Naltrexone ER/Bupropion ER [Contrave]